Gain Therapeutics is a biotechnology company developing small molecule therapeutics to treat diseases across, several therapeutics areas, including, central nervous system disorders, lysosomal storage disorders, metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. Co.'s primary product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease, including restoration of GCase function, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and increase of dopamine levels and improved locomotor function in animal models. The GANX average annual return since 2021 is shown above.
The Average Annual Return on the GANX average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether GANX average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the GANX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|